Endocrinologists called the main effects of “liquid” for overweight patients

Experts discussed tyrzepatide as a drug for the treatment of obesity. Its feature is a double effect on the receptors of GIP and GLP-1, while semaglutide affects only the receptors of GLP-1.

The discussion took place at a round table in Komsomolskaya Pravda, RTVI reports. The reason was the registration by the Ministry of Health of the Russian generic "Tirliday" in April 2026 - for the treatment of type 2 diabetes and obesity.

Professor Alexander Ametov proposed to perceive obesity not as a problem of excess weight, but as a violation of metabolic health. According to the WHO, a reduction in obesity is not projected in more than 185 countries by 2030, and obesity is diagnosed in 85-90% of patients with type 2 diabetes. Tyrzepatide reduces appetite, reduces cravings for sweets, slows the emptying of the stomach and prolongs the feeling of satiety; thanks to binding to albumin, the drug is administered once a week.

According to the results of the SURMOUNT-1 study, participants who received a maximum dose of 15 mg, on average, lost almost 23% of body weight and maintained the achieved result during treatment. In a group of 1,032 people with prediabetes, almost 99% of those who received the drug did not develop diabetes over three years, and the risk of developing it compared to placebo decreased by 94%.

In the TABFAT study, over 24 weeks, tirzepatide increased the activity and volume of brown adipose tissue, and some white fat acquired the properties of metabolically active “beige”. This allows us to talk about the drug not only as a means of weight loss, but also as a therapy that affects metabolism.

Doctors warn that treatment should be under the supervision of an endocrinologist. The drug is contraindicated in medullary thyroid cancer, and with diabetes, kidney disease or taking hypoglycemic drugs, dehydration and hypoglycemia are possible. After discontinuation of therapy, weight and metabolic risks may return if the patient does not change diet, physical activity and receive psychological support.

According to the participants of the discussion, a stable result is possible when combining the drug with protein nutrition, a gradual increase in activity and work with a psychologist.

"Tirliday" produces "Pharmasynthesis-Nord" in six dosages - from 2.5 to 15 mg. Nikita Punia, Vice President of Pharmasynthesis Group for Commerce, said that the plant was inspected by the Brazilian regulator ANVISA, and the quality of Tirlidea corresponds to the original drug.

Punia compared the cost of Tirlidea to the price of Mounjaro in Austria, where the initial dosage costs from 330 euros, that is, about 11 times more expensive than Tirlidea. According to the company, over five to six weeks after the start of sales, more than 100,000 people bought the drug. Puniya also said that in the forums, patients call "Tirliday" Lida and Lidochka.